DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022" report has been added to ResearchAndMarkets.com's offering.

The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, exhibiting a CAGR of 3.3% during the forecast period

Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018, respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Colorectal Cancer Drugs Market Overview

Chapter 5 Colorectal Cancer Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

Companies Mentioned

Amgen Bayer Bristol-Myers Squibb Eli Lilly Merck Roche Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/5zhbj6/colorectal_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005682/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Colon Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 02:46 PM/DISC: 08/23/2018 02:46 PM

http://www.businesswire.com/news/home/20180823005682/en